Holen Sie sich die Stockscreener-App
1.5608
3.47%
-0.0592
Schlusskurs vom Vortag:
$1.62
Offen:
$1.57
24-Stunden-Volumen:
3.58M
Relative Volume:
0.53
Marktkapitalisierung:
$468.58M
Einnahmen:
$188.87M
Nettoeinkommen (Verlust:
$-400.38M
KGV:
-1.0405
EPS:
-1.5
Netto-Cashflow:
$-260.90M
1W Leistung:
+11.70%
1M Leistung:
+33.66%
6M Leistung:
+18.47%
1J Leistung:
-23.72%
1-Tages-Spanne:
$1.51
$1.59
1-Wochen-Bereich:
$1.3735
$1.62
52-Wochen-Spanne:
$0.8511
$2.72
Pacific Biosciences Of California Inc Stock (PACB) Company Profile
Firmenname
Pacific Biosciences Of California Inc
Sektor
Branche
Telefon
650-521-8000
Adresse
1305 O'BRIEN DRIVE, MENLO PARK, CA
Vergleichen Sie PACB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PACB
Pacific Biosciences Of California Inc
|
1.56 | 426.53M | 188.87M | -400.38M | -260.90M | -1.50 |
|
ABT
Abbott Laboratories
|
131.81 | 230.73B | 43.11B | 13.94B | 6.78B | 7.9963 |
|
BSX
Boston Scientific Corp
|
95.58 | 141.37B | 18.49B | 2.50B | 3.49B | 1.6801 |
|
SYK
Stryker Corp
|
368.80 | 139.39B | 23.82B | 2.92B | 4.02B | 7.5574 |
|
MDT
Medtronic Plc
|
96.14 | 122.60B | 34.20B | 4.69B | 5.30B | 3.6218 |
|
EW
Edwards Lifesciences Corp
|
72.95 | 43.41B | 5.69B | 1.41B | 577.90M | 6.9828 |
Pacific Biosciences Of California Inc Stock (PACB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-11 | Herabstufung | UBS | Buy → Neutral |
| 2024-06-03 | Fortgesetzt | Jefferies | Buy |
| 2024-04-22 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-04-18 | Herabstufung | Goldman | Buy → Neutral |
| 2023-12-14 | Eingeleitet | Guggenheim | Neutral |
| 2023-12-14 | Eingeleitet | Stephens | Overweight |
| 2023-12-13 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-11-17 | Hochstufung | UBS | Neutral → Buy |
| 2023-10-31 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2023-09-28 | Eingeleitet | Bernstein | Outperform |
| 2023-07-05 | Fortgesetzt | JP Morgan | Overweight |
| 2023-06-30 | Eingeleitet | Goldman | Buy |
| 2023-05-10 | Eingeleitet | Barclays | Equal Weight |
| 2023-03-31 | Hochstufung | TD Cowen | Market Perform → Outperform |
| 2023-02-02 | Eingeleitet | UBS | Neutral |
| 2023-01-20 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-01-05 | Eingeleitet | Scotiabank | Sector Outperform |
| 2022-01-21 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2022-01-06 | Fortgesetzt | Piper Sandler | Neutral |
| 2021-10-15 | Fortgesetzt | Cowen | Market Perform |
| 2021-09-27 | Eingeleitet | Canaccord Genuity | Buy |
| 2021-02-11 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2020-11-03 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2020-10-02 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-09-09 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2020-06-02 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2020-03-09 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2019-10-15 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2019-04-02 | Herabstufung | Stephens | Overweight → Equal-Weight |
| 2018-10-19 | Eingeleitet | Cowen | Outperform |
| 2017-11-03 | Herabstufung | First Analysis Sec | Overweight → Equal-Weight |
| 2017-09-28 | Herabstufung | CL King | Buy → Neutral |
| 2016-11-03 | Bestätigt | Cantor Fitzgerald | Buy |
| 2016-06-27 | Eingeleitet | CL King | Buy |
| 2016-04-15 | Eingeleitet | First Analysis Sec | Overweight |
| 2016-02-04 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2016-01-04 | Bestätigt | Cantor Fitzgerald | Buy |
| 2015-10-23 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2015-08-27 | Eingeleitet | Cantor Fitzgerald | Buy |
| 2015-02-04 | Bestätigt | Maxim Group | Buy |
| 2013-09-26 | Bestätigt | Maxim Group | Buy |
| 2013-01-14 | Bestätigt | Maxim Group | Buy |
Alle ansehen
Pacific Biosciences Of California Inc Aktie (PACB) Neueste Nachrichten
PacBio (PACB) Unveils Cost-Saving Innovations for Sequencing Pla - GuruFocus
Further Upside For Pacific Biosciences of California, Inc. (NASDAQ:PACB) Shares Could Introduce Price Risks After 38% Bounce - simplywall.st
PacBio Announces Major Advances for Revio and Vega to Lower Genome Cost and Expand Multiomic Capabilities - Yahoo Finance
What makes Pacific Biosciences of California Inc. stock attractive to growth fundsJuly 2025 EndofMonth & Risk Adjusted Buy and Sell Alerts - newser.com
Analyzing recovery setups for Pacific Biosciences of California Inc. investorsDay Trade & Fast Momentum Entry Tips - newser.com
Market reaction to Pacific Biosciences of California Inc.’s recent newsJuly 2025 PreEarnings & Stepwise Entry and Exit Trade Signals - newser.com
PacBio (PACB) Stock Trades Up, Here Is Why - TradingView
Custom strategy builders for tracking Pacific Biosciences of California Inc.Weekly Stock Recap & High Return Stock Watch Alerts - newser.com
Pacific Biosciences Says HiFi Technology Selected for South Korean Pangenome Project - MarketScreener
Why Pacific Biosciences of California Inc. stock is favored by top institutionsQuarterly Performance Summary & High Yield Equity Trading Tips - newser.com
How resilient is Pacific Biosciences of California Inc. stock in market downturnsEarnings Summary Report & High Accuracy Buy Signal Tips - newser.com
PacBio's HiFi Sequencing Chosen for Korean Pangenome Project - GuruFocus
PacBio HiFi Technology Selected as Core Platform for South Korea’s National Pangenome Project - Yahoo Finance
Can Pacific Biosciences of California Inc. stock resist market sell offs2025 Technical Patterns & Free Community Supported Trade Ideas - newser.com
Does Pacific Biosciences of California Inc. stock trade at a discount to peersWeekly Risk Summary & Growth Focused Stock Pick Reports - newser.com
Statistical indicators supporting Pacific Biosciences of California Inc.’s strengthQuarterly Market Summary & Risk Controlled Stock Pick Alerts - newser.com
What analysts say about Pacific Biosciences of California Inc stockFundamental Stock Analysis & Small Entry Cost Stocks - earlytimes.in
Here's Why You Should Retain PacBio Stock in Your Portfolio for Now - sharewise.com
Weiss Ratings Reiterates Sell (E+) Rating for Pacific Biosciences of California (NASDAQ:PACB) - MarketBeat
Detecting price anomalies in Pacific Biosciences of California Inc. with AIEarnings Risk Report & Daily Growth Stock Tips - newser.com
What analysts say about Pacific Biosciences of California Inc P09 stockHealthcare Stock Analysis & Rapid Profit Growth - earlytimes.in
How HiFi sequencing achieves scalable microbial genomics without compromise - PacBio
Forecasting Pacific Biosciences of California Inc. price range with options dataWeekly Investment Recap & Community Verified Trade Alerts - newser.com
Is Pacific Biosciences of California Inc. (P09) stock resilient in recession scenariosIndex Update & Stock Portfolio Risk Management - newser.com
PacBio Stock Dips Despite Announcing Expanded Partnership With seqWell - MSN
Why Is PacBio (PACB) Stock Soaring Today - Yahoo Finance
PacBio (PACB) Technology Chosen for Major Longevity Study - GuruFocus
7,800 Genomes & Epigenomes: PacBio Powers Long Life Family Study with Revio, Q4 2025 Start - Stock Titan
Pacific Biosciences of California (NASDAQ:PACB) Stock Price Passes Above 200-Day Moving AverageHere's Why - MarketBeat
PacBio Expands Partnership with seqWell to Distribute LongPlex™ Multiplexing Kit for Enhanced Genomic Sequencing Solutions - Quiver Quantitative
Up to hundreds of samples — PacBio expands seqWell deal to distribute LongPlex Kit; global 2026 - Stock Titan
Why Pacific Biosciences of California (PACB) Outpaced the Stock Market Today - sharewise.com
Is Pacific Biosciences of California Inc. (P09) stock a buy before new product rollout2025 Breakouts & Breakdowns & Trade Opportunity Analysis Reports - newser.com
Will Pacific Biosciences of California Inc. stock outperform Nasdaq indexJuly 2025 Sector Moves & Reliable Breakout Forecasts - newser.com
Why Pacific Biosciences of California Inc. stock is rated strong buy2025 Year in Review & Long-Term Capital Growth Ideas - newser.com
Is this a good reentry point in Pacific Biosciences of California Inc.July 2025 Closing Moves & AI Powered Buy/Sell Recommendations - newser.com
Will Pacific Biosciences of California Inc. rebound enough to break evenJuly 2025 Earnings & Verified Momentum Watchlists - newser.com
Is Pacific Biosciences of California Inc. a candidate for recovery playJuly 2025 Pullbacks & Pattern Based Trade Signal System - newser.com
Applied Materials, GameStop And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Benzinga
Heatmap analysis for Pacific Biosciences of California Inc. and competitorsWeekly Loss Report & Reliable Price Breakout Alerts - newser.com
Barclays Maintains Pacific Biosciences of California(PACB.US) With Hold Rating, Maintains Target Price $1.5 - 富途牛牛
Can volume confirm reversal in Pacific Biosciences of California Inc.Portfolio Growth Summary & Weekly Breakout Watchlists - newser.com
Finanzdaten der Pacific Biosciences Of California Inc-Aktie (PACB)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.55%
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):